HIV Post-Exposure Prophylaxis for Pregnant Healthcare Worker
For a pregnant woman at 6 months gestation with a needle-stick exposure, initiate Zidovudine (ZDV/AZT) 600 mg daily (in 2-3 divided doses) plus Lamivudine (3TC) 150 mg twice daily (available as Combivir) immediately in the emergency department. 1
Rationale for This Specific Regimen in Pregnancy
The ZDV + 3TC combination is explicitly identified as "probably a safe regimen for pregnant HCP" in the U.S. Public Health Service guidelines 1. This is the only regimen in the guidelines with this specific pregnancy safety designation. The evidence supporting this recommendation includes:
- ZDV is associated with decreased risk of HIV transmission in the CDC case-control study of occupational HIV infection (OR 0.19,95% CI 0.06-0.52) 2
- Serious toxicity is rare when used for PEP
- Side effects are predictable and manageable with antimotility and antiemetic agents
- Can be given as a single tablet (Combivir) twice daily, improving adherence 1
Critical Timing
Start PEP within 72 hours of exposure—ideally within the first few hours. Do not delay initiation while waiting for source patient testing results 1. The window of opportunity exists because HIV initially replicates in dendritic cells before systemic spread 2.
Immediate ER Actions
Wound care first: Wash the needle-stick site thoroughly with soap and water 1
Rapid source patient assessment:
- Test source patient for HIV antibody using rapid testing if available 1
- Assess risk based on source patient's known HIV status, viral load if on treatment, and risk factors
- If source unknown or unavailable, assess exposure risk independently
Initiate the basic 2-drug regimen immediately (ZDV + 3TC) 1
Baseline testing: Draw baseline HIV antibody test on the exposed pregnant worker 1
Drugs to AVOID in Pregnancy
Do not use these agents as part of the initial regimen:
- Efavirenz: Explicitly contraindicated—"should not be used during pregnancy because of concerns about teratogenicity" 1
- Indinavir: "Must avoid this drug during late pregnancy" due to hyperbilirubinemia 1
- Stavudine (d4T) + Didanosine (ddI): Risk of fatal pancreatitis, lactic acidosis, and hepatitis; avoid this combination especially in pregnancy 1
When to Consider Expanded 3-Drug Regimen
If the exposure is high-risk (deep injury, visible blood on device, hollow-bore needle, source patient with high viral load or terminal AIDS), consider adding a third drug 2. For pregnancy, Nelfinavir is the safer protease inhibitor option if expansion is needed, as it has more pregnancy experience than other options 1. However, the basic 2-drug regimen (ZDV + 3TC) is appropriate for most occupational exposures.
Follow-Up Protocol
- Evaluate within 72 hours after exposure and monitor for drug toxicity for at least 2 weeks 1
- Continue PEP for 4 weeks total 3, 2
- HIV antibody testing schedule: baseline, 6 weeks, 3 months, and 6 months post-exposure 1
- Counsel on secondary transmission prevention: Advise against unprotected sex and blood donation for 3 months until serological confirmation of non-infection 4
- Monitor for acute retroviral syndrome symptoms during follow-up 1
Common Pitfalls to Avoid
- Delaying initiation: Every hour counts—start immediately, don't wait for complete risk assessment
- Choosing newer agents without pregnancy data: Stick with ZDV + 3TC which has the most extensive pregnancy safety profile
- Inadequate counseling: PEP is not 100% effective; the pregnant worker must understand continued precautions are necessary 2
- Poor adherence support: GI side effects are common with this regimen; provide antiemetics and antimotility agents proactively 1
Obstetric Considerations
The lopinavir + ritonavir + ZDV + lamivudine combination has been used long-term in pregnant women with chronic HIV infection without evidence of teratogenicity 4. However, for PEP (short 4-week course), the simpler 2-drug regimen (ZDV + 3TC) is preferred unless the exposure risk clearly warrants expansion.